MX2020003706A - Aminoimidazopiridazinas como inhibidores de cinasa. - Google Patents

Aminoimidazopiridazinas como inhibidores de cinasa.

Info

Publication number
MX2020003706A
MX2020003706A MX2020003706A MX2020003706A MX2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A MX 2020003706 A MX2020003706 A MX 2020003706A
Authority
MX
Mexico
Prior art keywords
aminoimidazopyridazines
kinase inhibitors
kinase
inhibitors
empty
Prior art date
Application number
MX2020003706A
Other languages
English (en)
Inventor
Carolyn Diane Dzierba
Amy C Hart
William J Pitts
Steven H Spergel
Guanglin Luo
Jianliang Shi
John E Macor
Michael E Mertzman
Jason M Guernon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020003706A publication Critical patent/MX2020003706A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La presente invención se refiere a compuestos que tienen la fórmula (I), y enantiómeros, y diastereómeros, estereoisómreos, sales de los mismos farmacéuticamente aceptables, (ver fórmula I) son útiles como inhibidores de cinasa, que incluyen modulación de RIPK1. Todas las variables son como se definen en la presente.
MX2020003706A 2017-10-30 2018-10-29 Aminoimidazopiridazinas como inhibidores de cinasa. MX2020003706A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578607P 2017-10-30 2017-10-30
US201862626853P 2018-02-06 2018-02-06
PCT/US2018/057968 WO2019089442A1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2020003706A true MX2020003706A (es) 2020-07-22

Family

ID=64332173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003706A MX2020003706A (es) 2017-10-30 2018-10-29 Aminoimidazopiridazinas como inhibidores de cinasa.

Country Status (22)

Country Link
US (1) US11440913B2 (es)
EP (1) EP3704118B1 (es)
JP (1) JP7228586B2 (es)
KR (1) KR102662197B1 (es)
CN (1) CN111566103B (es)
AU (1) AU2018361249B2 (es)
BR (1) BR112020007557A2 (es)
CA (1) CA3080402A1 (es)
CY (1) CY1124984T1 (es)
DK (1) DK3704118T3 (es)
ES (1) ES2905948T3 (es)
HR (1) HRP20220297T1 (es)
HU (1) HUE058292T2 (es)
IL (1) IL274207B2 (es)
LT (1) LT3704118T (es)
MX (1) MX2020003706A (es)
PL (1) PL3704118T3 (es)
PT (1) PT3704118T (es)
RS (1) RS62974B1 (es)
SG (1) SG11202003824PA (es)
SI (1) SI3704118T1 (es)
WO (1) WO2019089442A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102549952B1 (ko) 2017-02-13 2023-06-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노트리아졸로피리딘
WO2019147782A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
CN115087651A (zh) * 2019-10-03 2022-09-20 百时美施贵宝公司 作为激酶抑制剂的吲唑甲酰胺
WO2021168521A1 (en) * 2020-02-27 2021-09-02 Anaxis Pharma Pty Ltd Inhibitors of necroptosis
CA3193415A1 (en) * 2020-10-13 2022-04-21 The Johns Hopkins University Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
JP5520831B2 (ja) * 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
EP2393813B1 (en) * 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
CN104395298A (zh) 2012-06-22 2015-03-04 住友化学株式会社 稠合杂环化合物
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
WO2014081756A1 (en) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. S1p and/or atx modulating agents
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CA2914668A1 (en) 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
CA2958645A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
CN109311902B (zh) 2016-05-05 2022-07-15 Bial研发投资股份有限公司 取代的咪唑并[1,2-b]哒嗪、咪唑并[1,5-b]哒嗪、相关化合物及其用途
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
KR102549952B1 (ko) 2017-02-13 2023-06-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노트리아졸로피리딘
WO2019147782A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
EA202190759A1 (ru) 2018-09-13 2021-06-17 Бристол-Маерс Сквибб Компани Индазолкарбоксамиды в качестве ингибиторов киназ
MX2021002509A (es) 2018-09-13 2021-04-28 Bristol Myers Squibb Co 1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1).
WO2020097400A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof

Also Published As

Publication number Publication date
IL274207A (en) 2020-06-30
JP7228586B2 (ja) 2023-02-24
CY1124984T1 (el) 2023-01-05
CA3080402A1 (en) 2019-05-09
US11440913B2 (en) 2022-09-13
SG11202003824PA (en) 2020-05-28
IL274207B (en) 2022-12-01
BR112020007557A2 (pt) 2020-09-24
CN111566103B (zh) 2023-06-23
KR20200078591A (ko) 2020-07-01
EP3704118A1 (en) 2020-09-09
JP2021501179A (ja) 2021-01-14
ES2905948T3 (es) 2022-04-12
RS62974B1 (sr) 2022-03-31
KR102662197B1 (ko) 2024-04-29
IL274207B2 (en) 2023-04-01
HRP20220297T1 (hr) 2022-05-13
PT3704118T (pt) 2022-02-14
WO2019089442A8 (en) 2019-06-27
WO2019089442A1 (en) 2019-05-09
LT3704118T (lt) 2022-02-25
AU2018361249B2 (en) 2022-08-25
SI3704118T1 (sl) 2022-04-29
US20200277296A1 (en) 2020-09-03
DK3704118T3 (da) 2022-03-14
CN111566103A (zh) 2020-08-21
AU2018361249A1 (en) 2020-06-11
EP3704118B1 (en) 2022-01-12
HUE058292T2 (hu) 2022-07-28
PL3704118T3 (pl) 2022-04-04

Similar Documents

Publication Publication Date Title
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
MX2020004287A (es) Procesamiento de biomasa.
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020003430A (es) Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana.
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
MX2017000363A (es) Inhibicion de la via de notch.
MX2020004255A (es) Compuesto de pirimidina como inhibidor de las janocinasas.
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020003760A (es) Formulaciones de niraparib.
MX2020003712A (es) Union giratoria de pasaje multiple.
MX2020004455A (es) Derivados de pirrolopirazina como inhibidores de integrina alfa v.
MX2020004424A (es) Formulacion aerosolizable.
MX2020003439A (es) Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
MX2020004245A (es) Estabilizador mejorado para poliamidas.
MX2020002908A (es) Composicion acuosa de polimeros.
MX2020003611A (es) Metodos de refuerzo del pozo.
MX2020004048A (es) Formas cristalinas de lenalidomida.
MX2020004422A (es) Formulacion vaporizable saborizada.
MX2020003440A (es) Red de seguridad.
GB201807845D0 (en) Kinase Inhibitors
MX2020003487A (es) Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos.
MX2020003703A (es) Composiciones de sabor.
MX2020004664A (es) Dispositivo generador de humo mejorado.